Skip to main content

Core Curriculum: Management of ART in Special Populations

No Ratings

AAHIVM Course Banner
1.0 CEUs
Management of ART in Special Populations

Module Description  The Core Curriculum is developed out of the Academy's Fundamentals of HIV Medicine textbook and is an ideal way to learn the basics of HIV prevention, care and treatment or to gain a quick update on specific topics in HIV care. Pregnant people, infants, children, injection drug users and older adults with HIV present specific and important challenges related to the treatment and monitoring of HIV.

Credit Dates 06/20/2024 – 06/19/2025

Jointly provided by Partners for Advancing Clinical Education (PACE) and the American Academy of HIV Medicine.

This activity is supported by independent educational grants from Merck & Co. and ViiV Healthcare.
Learning Objectives
  • Apply knowledge of physiologic changes and prevention of perinatal transmission to provide optimal management for pregnant people with HIV
  • Appraise advances in ART for the prevention of perinatal transmission
  • Employ current guidelines for management of ART in children
  • Relate treatment concerns, including drug-drug interactions, that are clinically significant for older persons with HIV
  • Inventory outcomes of clinical trials focused on older people with HIV
  • Demonstrate knowledge of the intersecting problems of substance use and risk of HIV
  • Illustrate problems related to substance use and treatment with respect to ART management, coinfection, mental health issues and other complications

Target AudienceThis activity is intended for physicians, PAs, NPs, RNs, and pharmacists who are engaged in the care of people with HIV.

Estimated Time to Complete the Activity: 60 minutes

PresentersAshwin Gupta, PA-C, AAHIVS
Penn Presbyterian Medical Center
University of Pennsylvania
Philadelphia, PA

Instructions for CreditThere are no fees for participating and receiving CME/CE credit for this activity.

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive CE credit, learners must follow these steps during the period from June 20, 2024 through June 19, 2025:

  1. Review the objectives and disclosures
  2. Study the educational content
  3. Complete the activity evaluation
For Pharmacists: Upon successfully completing the post-test (if applicable) with a score of 75% or better and the online evaluation, your credit will be submitted to CPE Monitor. Please check your NABP account within thirty (30) days to make sure the credit has posted.

If you have questions regarding the certification of this activity, please contact PACE by visiting ttps://partnersed.com.

Joint Accreditation Statement In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and the American Academy of HIV Medicine. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Education PACE designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education PACE designates this continuing education activity for 1.o contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - JA4008073-9999-24-151-H02-P)

Type of Activity: Knowledge

Continuing Nursing Education The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hours and 1.0 pharmacotherapy hours for APRN.

Disclosure of Conflict of Interest PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
 
Mr. Gupta has nothing to disclose.

Media: Internet

Computer System Requirements
This program requires the use of an internet-connected computer or device and a modern web browser capable of streaming video.

Disclosure of Unlabeled UseThis educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DisclaimerParticipants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.